Harmony Biosciences Holdings, Inc.
corporate_fare Company Profile
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for HRMY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for HRMY spans 10-Q, 8-K, 144, DEF 14A.
Recent high-impact activity:
- Harmony 10-Q: Q3 Revenue $268.9M, $1.05B Cash, R&D Up 30% on MSN Milestone
- Harmony Q3: WAKIX Revenue $268.9M, Guidance Reiterated, BP-205 MAD Data Positive
- Harmony Biosciences Posts 81-Cent Q3 EPS
- Wakix Patent Closing Arguments Send Harmony Shares Down 7%
- Harmony Biosciences Taps Peter Anastasiou as CEO, Reaffirms $1B+ 2026 Outlook
Financial Snapshot
Short Interest & Short Volume
5.63 days to coverFINRA reported short interest of 6,664,944 shares in HRMY as of the October 30, 2026 settlement, a 23.1% increase from the prior period — about 5.6 days to cover at its recent average daily volume. On November 20, 2026, 60.1% of HRMY volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.